Zoetis Inc.

ZTS · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$642K – $2.0M 22 disclosures · 10 bought / 12 sold · last Aug 28, 2026
Kurt Schrader D · HOUSE · OR	$100K – $250K $37K – $93K today 1 filing · last Jan 6, 2022
Ro Khanna D · HOUSE · CA	−$451K – $676K −$281K – $458K today 75 filings · last Aug 3, 2026
Markwayne Mullin R · SENATE · OK	−$63K – $148K −$44K – $67K today 8 filings · last Nov 10, 2025
Shelley Moore Capito R · SENATE · WV	$15K – $50K $6K – $20K today 1 filing · last Feb 27, 2024
Thad Cochran R · HOUSE · MS	$15K – $50K $20K – $65K today 1 filing · last Jun 13, 2017
K. Michael Conaway R · HOUSE · TX	$4K – $60K $4K – $61K today 4 filings · last Jan 8, 2019
Alan S. Lowenthal D · HOUSE · CA	−$63K – $112K −$86K – $150K today 8 filings · last Aug 26, 2022
Byron Donalds R · HOUSE · FL	$2K – $30K $1K – $22K today 2 filings · last Jun 9, 2026
John R. Curtis R · SENATE · UT	−$12K – $44K −$5K – $26K today 4 filings · last Dec 4, 2023

Recent transactions

Trades from Mar 13, 2026 – Sep 18, 2026

Politician	Type	Filed after	Amount
Gilbert Ray Cisneros, Jr. D · HOUSE · CA-31	Buy	24 days Sep 18, 2026 → Oct 12, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	41 days Aug 28, 2026 → Oct 8, 2026	≥$15K
Donald Trump R · EXECUTIVE	Sell	48 days Aug 21, 2026 → Oct 8, 2026	≥$500K
Donald Trump R · EXECUTIVE	Buy	52 days Aug 17, 2026 → Oct 8, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	59 days Aug 10, 2026 → Oct 8, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	59 days Aug 10, 2026 → Oct 8, 2026	≥$500K
Donald Trump R · EXECUTIVE	Sell	57 days Jul 27, 2026 → Sep 22, 2026	≥$50K
Donald Trump R · EXECUTIVE	Sell	60 days Jul 24, 2026 → Sep 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	61 days Jul 23, 2026 → Sep 22, 2026	≥$15K
Donald Trump R · EXECUTIVE	Buy	64 days Jul 20, 2026 → Sep 22, 2026	≥$500K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

1,493

13F shares

401.4M

Total invested

$28.9B

Ownership

95.1%

New positions

173

Closed positions

352

Increased positions

683

Reduced positions

606

Put/Call ratio

0.89

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	39.4M	$2.8B	+10.81%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	26M	$1.9B	−0.17%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	23.9M	$1.7B	−0.45%
STATE STREET CORP	9/22/2026	19.7M	$1.4B	+1.78%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO	8/12/2026	15.9M	$1.1B	+0.00%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	13.3M	$951.8M	+17.10%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	9.4M	$677.2M	−7.15%
MORGAN STANLEY	8/13/2026	8.9M	$638.0M	−37.23%
NORDEA INVESTMENT MANAGEMENT AB	8/5/2026	6.6M	$471.7M	+12.40%
DEUTSCHE BANK AG\	8/7/2026	5.9M	$420.5M	+5.78%
NORTHERN TRUST CORP	8/13/2026	5.5M	$398.3M	−0.07%
INVESCO LTD.	8/14/2026	5.5M	$396.9M	+55.97%
FIL LTD	8/13/2026	5.4M	$386.7M	−1.92%
NORGES BANK	8/12/2026	4.7M	$337.0M	—
VAN ECK ASSOCIATES CORP	8/14/2026	4.3M	$305.6M	+7.68%
FLOSSBACH VON STORCH AG	8/10/2026	4.2M	$302.6M	—
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	4M	$287.7M	—
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	4M	$287.7M	+7.71%
AMUNDI	8/11/2026	4M	$286.6M	+25.97%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	3.9M	$282.0M	−10.76%
BANK OF AMERICA CORP /DE/	8/14/2026	3.9M	$282.0M	−18.77%
UBS GROUP AG	8/13/2026	3.6M	$261.8M	+30.14%
LEGAL & GENERAL GROUP PLC	8/14/2026	3.6M	$256.4M	−2.28%
DIAMOND HILL CAPITAL MANAGEMENT INC	8/6/2026	3.6M	$255.6M	+21.52%
BANK OF NEW YORK MELLON CORP	8/6/2026	3.3M	$238.7M	−14.81%

Insider transactions

Insider	Type	Transacted	Price	Date
Fuller Julie	F-INKIND	274	$69.83	Sep 30
Fuller Julie	M-EXEMPT	799	—	Sep 30
Fuller Julie	M-EXEMPT	799	—	Sep 30
Stetter Mark	A-AWARD	342	—	Sep 17
Saccaro James	A-AWARD	81.1K	—	Aug 31
Saccaro James		0	—	Aug 17
Damelio Frank A	G-GIFT	6.7K	—	Aug 7
Joseph Wetteny	A-AWARD	363	—	Jul 10
Ferran Astorga Jeannette	A-AWARD	45	—	Jul 10
Lagano Roxanne	A-AWARD	315	—	Jul 10

Analyst consensus

Hold32 analysts

Bearish · 0 · Hold · 18 · Bullish · 14

Earnings history

	EPS	Estimate
Q3 2024	$1.58	$1.46	Beat
Q4 2024	$1.40	$1.37	Beat
Q1 2025	$1.48	$1.41	Beat
Q2 2025	$1.76	$1.62	Beat
Q3 2025	$1.70	$1.62	Beat
Q4 2025	$1.48	$1.40	Beat
Q1 2026	$1.53	$1.60	Miss
Q2 2026	$1.87	$1.85	Beat

Peers

Company overview

IPO dateFeb 1, 2013

CEOKristin C. Peck

Employees14,500

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUS

ExchangeNew York Stock Exchange

Websitewww.zoetis.com

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.